A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab or a Rituximab Containing Therapy

Trial Profile

A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab or a Rituximab Containing Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Bendamustine (Primary) ; Ofatumumab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Marginal-zone-B-cell-lymphoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 17 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 19 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2021 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top